Gene therapy progress and prospects cancer: oncolytic viruses. (Q34770611)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418413%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Gene therapy progress and prospects cancer: oncolytic viruses (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418413%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418413%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

D Kirn

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418413%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

17 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418413%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418413%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418413%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418413%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

877-884

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18418413%20AND%20SRC:MED&resulttype=core&format=json

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

An immunocompetent murine model for oncolysis with an armed and targeted measles virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Engineering oncolytic measles virus to circumvent the intracellular innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Synergistic antitumor effects of immune cell-viral biotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Adenovirus-induced extracellular signal-regulated kinase phosphorylation during the late phase of infection enhances viral protein levels and virus progeny

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

Immune analysis on mtHSV mediated tumor therapy in HSV-1 seropositive mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

7 January 2021

Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

7 January 2021

Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

7 January 2021

Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

7 January 2021

A novel system to study adenovirus tropism to normal and malignant colon tissues

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

7 January 2021

Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

7 January 2021

Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.72

7 January 2021